These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34001723)

  • 1. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
    Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
    J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin ET
    Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
    Mirabito Colafella KM; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Baelde HJ; van den Meiracker AH; Touyz RM; Danser AHJ; Versmissen J
    Cardiovasc Res; 2020 Aug; 116(10):1779-1790. PubMed ID: 31593221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprocitentan: First Approval.
    Dhillon S
    Drugs; 2024 Jul; 84(7):841-847. PubMed ID: 38833193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.
    Heidari Nejad S; Azzam O; Schlaich MP
    Future Cardiol; 2024; 20(9):435-445. PubMed ID: 38953510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL; Turgeon A; Deng LY
    Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprocitentan and the endothelin system in resistant hypertension.
    Clozel M
    Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
    Rafnsson A; Shemyakin A; Pernow J
    Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit
    Takahashi S; Horie R; Yokoyama Y
    Nihon Yakurigaku Zasshi; 2017; 149(1):49-58. PubMed ID: 28049880
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprocitentan: A new development of resistant hypertension.
    Yao Y; Fan B; Yang B; Jia Z; Li B
    J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
    Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
    Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endothelin system in pulmonary arterial hypertension.
    Galié N; Manes A; Branzi A
    Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.
    Xu J; Jiang X; Xu S
    Drug Discov Today; 2023 Nov; 28(11):103788. PubMed ID: 37742911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Role of Endothelin in Early Vascular Aging.
    Trindade M; Oigman W; Fritsch Neves M
    Curr Hypertens Rev; 2017; 13(1):33-40. PubMed ID: 28413991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
    Sidharta PN; Fischer H; Dingemanse J
    Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin antagonists in hypertension and kidney disease.
    Meyers KE; Sethna C
    Pediatr Nephrol; 2013 May; 28(5):711-20. PubMed ID: 23070275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.